SWTX241220C40000
- 1.88
- +0.53+39.26%
SpringWorks Therapeutics Newsroom
J.P. Morgan Sticks to Their Buy Rating for Springworks Therapeutics (SWTX)
SpringWorks Therapeutics Initiated at Outperform by Evercore ISI Group
SpringWorks Therapeutics Analyst Ratings
Evercore Initiates SpringWorks Therapeutics(SWTX.US) With Buy Rating, Announces Target Price $60
Express News | SpringWorks Therapeutics Inc : JP Morgan Raises Target Price to $70 From $68
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
SpringWorks' Q3 Loss Narrower Than Expected, Revenues Miss Mark
A Quick Look at Today's Ratings for SpringWorks Therapeutics(SWTX.US), With a Forecast Between $58 to $74
Barclays Sticks to Its Buy Rating for Springworks Therapeutics (SWTX)
Buy Rating Reaffirmed for Springworks Therapeutics Amid Promising Outlook for Ogsiveo and Mirdametinib
Optimistic Future for Springworks Therapeutics Amid Packaging Transition and Market Expansion
SpringWorks Therapeutics, Inc. (SWTX) Q3 2024 Earnings Call Transcript Summary
SpringWorks Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Springworks Therapeutics: Strong Cash Position and Promising Drug Approval Outlook Justify Buy Rating
Express News | SpringWorks Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $74 From $76
SpringWorks Therapeutics | 8-K: SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
SpringWorks Therapeutics | 10-Q: Q3 2024 Earnings Report
SpringWorks Therapeutics to Participate in the Jefferies London Healthcare Conference
Springworks Therapeutics' Q3 Net Loss Narrows
SpringWorks Therapeutics (SWTX) Reports Q3 Loss, Lags Revenue Estimates